OpenAlex
PricingAboutJobs
Log inGet started
Work

Results of GROC-rev salvage regimen: Gemcitabine, rituximab, and oxaliplatin chemotherapy with revlimid for relapsed/refractory aggressive non-Hodgkin lymphoma (NHL).

HTML

Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
DOI: 10.1200/jco.2017.35.15_suppl.7556
Authors: Fernando Cabanillas, Idalia Liboy, Alexis Cruz, Pedro Gil Solivan, Noridza Rivera, Wandaly Ibis Pardo, Mirelis Acosta
Institution: Auxilio Mutuo Hospital
Language: English

Topic: Lymphoma Diagnosis and Treatment
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Keywords: relapsed/refractory non-Hodgkin lymphoma, aggressive lymphoma, lenalidomide, salvage chemotherapy, gemcitabine, rituximab, oxaliplatin, progression-free survival, overall survival, diffuse large B-cell lymphoma, follicular lymphoma, PTCL, autologous stem cell transplantation
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2891761816
Cites:
Cited by: 2
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security